Navigation Links
New Insights on Who Should Take Erbitux for Colon Cancer
Date:10/26/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, Oct. 26 (HealthDay News) -- New research challenges previous assumptions about how to treat metastatic colon cancer in patients with a certain genetic mutation.

While guidelines have recommended that people with this type of cancer and mutations in their KRAS gene should not receive the targeted therapy cetuximab (Erbitux), a new study finds that a subset of these patients might actually benefit from taking the drug.

"Those drugs [cetuximab and its sister medication, panitumumab (Vectibix)] have been shown in a number of other studies to be less effective in patients who have mutations of the KRAS gene," explained Dr. Durado Brooks, director of colorectal cancer at the American Cancer Society. "Those studies have been so convincing that the National Comprehensive Cancer Network [which produces treatment guidelines] added KRAS testing as an element of decision-making for using these drugs to determine whether or not these drugs are likely to be useful."

This new study, appearing in the Oct. 27 issue of the Journal of the American Medical Association, suggests that researchers and clinicians both may need to drill down further in attempting to decipher which patients will benefit most from different targeted therapies.

"Before, we have been lumping [different] KRAS mutations together," Brooks said. "This current article is saying we may have been overly simplistic in our approach."

"It's a provocative report," added Dr. Steven Cohen, a medical oncologist with Fox Chase Cancer Center in Philadelphia. "The mantra has been to lump [the two KRAS] mutations together. This gives us reason to second-guess ourselves that we should not be excluding patients [with this one mutation] from this type of treatment."

Here, a group of European researchers looked at 579 patients for whom chemotherapy had not worked and who had taken cetuximab in previous clinical trials.

For the analysis, patients were separated out, depending on whether they had the KRAS codon 12 mutation or the KRAS codon 13 mutation.

Patients with the KRAS codon 13 mutation who were treated with cetuximab lived an average of 7.6 months, versus 5.7 months in those with the other mutation. Also, an average of four months transpired before disease progression, versus about two months in the control group, the investigators found.

Those with the KRAS codon 13 mutation didn't respond as well to the drug as people with a normal version of the gene, but they still responded.

While some experts may quibble with the study's methodology -- pooling data from several already-completed trials -- this may be the only way that enough patients with this relatively rare (codon 13) mutation could be collected for a legitimate analysis, Cohen noted.

Maybe 5 percent of patients with metastatic colorectal cancer, which is cancer that has spread, have this particular KRAS mutation, Cohen said.

Not only will more research need to be done before giving cetuximab to people with the codon 13 mutation becomes common practice, but doctors, the cancer network and insurance companies will have to get on board, Cohen noted.

The cost of cetuximab can be $3,000 a week or higher (the treatment is delivered weekly).

"It's a major cost issue," Cohen said.

More information

The U.S. National Cancer Institute has more on treatments for colorectal cancer.

SOURCES: Durado Brooks, M.D., director, colorectal cancer, American Cancer Society, Atlanta; Steven Cohen, M.D., medical oncologist, Fox Chase Cancer Center, Philadelphia; Oct. 27, 2010, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sodium MRI gives new insights into detecting osteoarthritis, NYU researchers find
2. Snake venom studies yield insights for development of therapies for heart disease and cancer
3. Cell symposia meeting, Influenza: Translating basic insights, to be held Dec. 2-4, 2010
4. From head to toe: Deep insights from whole body MRI
5. Emerald Express International to be Featured on ‘Insights' with Hugh Downs this Spring in a Segment that Spotlights Glutathione and Anti-Aging
6. Expert Insights on Health Data Sharing, Collaboration, Quality and Meaningful Use Featured in Latest Carefx Position Paper
7. Gut bacteria offer new insights -- and hope -- for people with celiac disease
8. Industry Veteran Bob O'Hara to Share Insights on Enterprise WLAN Market at Interop Las Vegas 2010
9. Study Offers Insights Into Male Pattern Baldness
10. New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population
11. New Insights Into Whos At Risk With Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Insights on Who Should Take Erbitux for Colon Cancer
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... DC (PRWEB) , ... May 26, 2016 , ... There ... National Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight ... dogs, 63 percent say grilling is their favorite way to cook a hot dog, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... discovery of thousands of defective respirators, according to court documents and SEC filings. ... of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card will ... country. The nonprofit Hope For Heroes partnered with the leading provider of free ... military veterans, as well as police, firemen, and EMS professionals across the country, and ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: